A detailed history of Cibc Private Wealth Group, LLC transactions in Xencor Inc stock. As of the latest transaction made, Cibc Private Wealth Group, LLC holds 17,563 shares of XNCR stock, worth $439,250. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,563
Previous 17,563 -0.0%
Holding current value
$439,250
Previous $332,000 6.33%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$16.53 - $21.42 $41,325 - $53,550
2,500 Added 16.6%
17,563 $372,000
Q4 2022

Feb 13, 2023

SELL
$24.79 - $30.86 $24,790 - $30,860
-1,000 Reduced 6.23%
15,063 $392,000
Q3 2022

Nov 14, 2022

SELL
$24.62 - $32.44 $36,930 - $48,660
-1,500 Reduced 8.54%
16,063 $417,000
Q1 2022

May 16, 2022

SELL
$26.68 - $41.63 $26,680 - $41,630
-1,000 Reduced 5.39%
17,563 $469,000
Q1 2021

May 12, 2021

SELL
$40.81 - $53.88 $20,405 - $26,940
-500 Reduced 2.62%
18,563 $799,000
Q3 2020

Nov 03, 2020

BUY
$30.09 - $43.02 $573,605 - $820,090
19,063 New
19,063 $739,000
Q2 2020

Aug 13, 2020

SELL
$27.76 - $33.42 $556,948 - $670,505
-20,063 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$20.69 - $37.79 $20,690 - $37,790
-1,000 Reduced 4.75%
20,063 $599,000
Q3 2019

Oct 16, 2019

SELL
$33.73 - $46.27 $50,594 - $69,405
-1,500 Reduced 6.65%
21,063 $710,000
Q2 2018

Aug 02, 2018

SELL
$28.41 - $42.41 $28,410 - $42,410
-1,000 Reduced 4.24%
22,563 $835,000
Q1 2018

May 17, 2018

SELL
$21.18 - $33.78 $211,800 - $337,800
-10,000 Reduced 29.79%
23,563 $706,000
Q4 2017

Feb 12, 2018

SELL
$19.29 - $24.83 $140,045 - $180,265
-7,260 Reduced 17.78%
33,563 $736,000
Q3 2017

Nov 14, 2017

BUY
$19.61 - $23.35 $800,539 - $953,217
40,823
40,823 $936,000

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.49B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Cibc Private Wealth Group, LLC Portfolio

Follow Cibc Private Wealth Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc Private Wealth Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cibc Private Wealth Group, LLC with notifications on news.